Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Abderrahman B, Maximov PY, Curpan RF, Fanning SW, Hanspal JS, Fan P, Foulds CE, Chen Y, Malovannaya A, Jain A, Xiong R, Greene GL, Tonetti DA, Thatcher GRJ, Jordan VC. Abderrahman B, et al. Among authors: thatcher grj. Mol Cancer Ther. 2021 Jan;20(1):11-25. doi: 10.1158/1535-7163.MCT-20-0563. Epub 2020 Nov 11. Mol Cancer Ther. 2021. PMID: 33177154 Free PMC article.
SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, Wang Y, Thayer EN, Scism RA, Michalsen BT, Xiong R, Siklos MI, Bolton JL, Thatcher GR. Hemachandra LP, et al. Cancer Prev Res (Phila). 2014 May;7(5):505-15. doi: 10.1158/1940-6207.CAPR-13-0296. Epub 2014 Mar 5. Cancer Prev Res (Phila). 2014. PMID: 24598415 Free PMC article.
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y, Gutgesell LM, Xiong R, Zhao J, Li Y, Rosales CI, Hollas M, Shen Z, Gordon-Blake J, Dye K, Wang Y, Lee S, Chen H, He D, Dubrovyskyii O, Zhao H, Huang F, Lasek AW, Tonetti DA, Thatcher GRJ. Lu Y, et al. Among authors: thatcher grj. J Med Chem. 2019 Dec 26;62(24):11301-11323. doi: 10.1021/acs.jmedchem.9b01580. Epub 2019 Dec 10. J Med Chem. 2019. PMID: 31746603 Free PMC article.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, Strum JC, Thatcher GRJ, Norris JD. Andreano KJ, et al. Among authors: thatcher grj. Breast Cancer Res Treat. 2020 Apr;180(3):635-646. doi: 10.1007/s10549-020-05575-9. Epub 2020 Mar 4. Breast Cancer Res Treat. 2020. PMID: 32130619 Free PMC article.
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Li Y, Zhao J, Gutgesell LM, Shen Z, Ratia K, Dye K, Dubrovskyi O, Zhao H, Huang F, Tonetti DA, Thatcher GRJ, Xiong R. Li Y, et al. Among authors: thatcher grj. J Med Chem. 2020 Jul 9;63(13):7186-7210. doi: 10.1021/acs.jmedchem.0c00456. Epub 2020 Jun 15. J Med Chem. 2020. PMID: 32453591 Free PMC article.
150 results